Clinical Trial

Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib

Study acronym: CABOGEN
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 12, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
CABOGEN is a Observational, retrospective, multicenter study that will enroll patients with metastatic clear cell renal carcinoma (mccRCC) treated with cabozantinib after one or more previous lines of treatment that included TKIs, immune checkpoint inhibitors or mTOR inhibitors.
Trial Details
NCT Number NCT06548867
Lead Sponsor Gruppo Oncologico Italiano di Ricerca Clinica
Collaborators: Yghea, Ipsen
Conditions Metastatic Renal Cell Carcinoma
Enrollment 80 participants
Start Date 2024-05-28
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-08-12